Bayer NUBEQA (Darolutamide) 300 mg Tablets Instructions for Use

Darolutamide tablets, for the treatment of adult patients with high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC).


Bayer NUBEQA (Darolutamide) 300 mg Tablets Instructions for Use - cover page
Brand
Bayer
Category
Drugs
Document type
Other
Language
Chinese
Pages
14
File format
PDF
File size
570 KB
Published
30 October, 2023
Updated
30 October, 2023
MD5 checksum
E31C558F9F82B0D9958B8B87C1D2183B

About this manual

This Chinese-language instruction leaflet covers NUBEQA (darolutamide) 300 mg film-coated tablets. It states that darolutamide is indicated for adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis.

The leaflet describes the tablet composition and appearance, the recommended dose of 600 mg twice daily with food, dose adjustments for severe renal or moderate hepatic impairment, adverse reactions from the ARAMIS study, contraindications, warnings, drug interactions, and pregnancy/lactation precautions. This manual is written in Chinese.

What's inside

  • Ingredients
  • Appearance
  • Indications
  • Dosage and Administration
  • Special Populations
  • Adverse Reactions
  • Contraindications
  • Warnings and Precautions
  • Drug Interactions
  • Use in Pregnancy and Lactation

Specifications

Strength300 mg
Recommended dosage600 mg twice daily, orally
Total daily dose1200 mg
Molecular formulaC19H19ClN6O2
Molecular weight398.85
AppearanceWhite or off-white oval film-coated tablets
Tablet imprint300 on one side; BAYER on the other

Frequently asked questions

What is NUBEQA indicated for?

It is indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis.

What is the recommended dose of NUBEQA?

The recommended dose is 600 mg (two 300 mg film-coated tablets) taken orally twice daily, for a total daily dose of 1200 mg.

What should a patient do if a dose is missed?

Take it as soon as remembered before the next scheduled dose; do not take two doses at the same time to make up for a missed dose.

What starting dose is recommended for severe renal impairment?

For severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2), the recommended starting dose is 300 mg twice daily.

Download PDF (570 KB)

More Bayer Manuals


View all Bayer manuals →